AXGN Earnings

AXGN reported its earnings on 2026-03-02, showcasing a revenue of 0.00 against an estimate of 57.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.01 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following AXGN's earnings announcement on 2026-03-02, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, AXGN's stock price tends to shift by an average of -2.99% in the 10 days leading up to earnings and -2.32% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate AXGN’s annual revenue to reach 58.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.03% and EPS estimates Revise Upward by 0.11% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between AXGN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.03%, while EPS estimates moved Revise Upward by 0.11% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AXGN's stock price typically moves by -2.99% in the 10 days before its earnings and -2.32% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 58.00M.

The raised revenue growth guidance, strong gross margin, and expected net cash flow positivity indicate strong financial health. The BLA approval for Avance Nerve Graft is a significant catalyst, promising market exclusivity and expansion. The strategic expansion in sales force and surgeon training aligns with growth initiatives. Despite management's vague responses on some aspects, the overall sentiment from the earnings call and strategic updates is positive, suggesting a likely stock price increase.